Klaus Breiner
Financial Officer
Medicine
Am-pharma BV
Netherlands
Biography
Klaus is a venture capital investor with BB Biotech Ventures at Bellevue Group. Klaus has invested in numerous emerging biotech and pharma companies, in both the US and Europe. His other current and past board assignments include Agendia BV, Alpex Pharma SA, Cadence Pharmaceuticals Inc. (now public), Glycart Biotechnology AG (acquired by Roche), Orthocon Inc., Pevion Biotech AG and Vaximm AG. Prior to joining Bellevue, Klaus was an investment manager at another European private equity firm and a business consultant with Booz, Allen & Hamilton.
Research Interest
Molecular Biology
